Author made it clear this was an educational essay, but concluding the problem has very limited therapeutic applications comes across like a bit of a take down for Atomic AI's platform.
RNAs so far have been very bad drug targets. That is to a large part inherent in their properties, they have fewer different components (4 bases compared to 20 amino acids) and the RNA backbone is strongly charged and interactions with something like that are generally unspecific. Odds are that RNA will remain a bad drug target for almost all cases.
Source: PhD in RNA modifications